Immutep Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Immutep Ltd with three other companies in this sector in Australia: Cellmid Limited (2019 sales of 7.47 million Australian Dollars [US$5.11 million] ), Bionomics Limited (4.03 million Australian Dollars [US$2.76 million] of which 176% was Contract Services), and Imugene Limited (4.54 million Australian Dollars [US$3.11 million] of which 100% was Health technologies).

Sales Analysis. During the year ended June of 2019, sales at Immutep Ltd were A$6.03 million (US$4.13 million). This is a decrease of 14.2% versus 2018, when the company's sales were A$7.03 million. Contributing to the drop in overall sales was the 17.7% decline in Cancer Immunotherapy, from A$6.85 million to A$5.64 million. . However, these declines were partially offset by the increase in sales of Unallocated (up 270.7% to A$1.85 million) .